Cited by 110Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and ManagementImmunotherapy and Immune Responses

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Safety and efficacy of ipilimumab to treat advanced melanoma in the setting of liver transplantation

Open access

Morales, Rita E, Shoushtari, Alexander N, Walsh, Michelle M, Grewal, Priya, Lipson, Evan J, Carvajal, Richard D·2015·Journal for ImmunoTherapy of Cancer

DOI 10.1186/s40425-015-0066-0PMC PMC4469313

Open this paper in CoChat — free account Open PDF

Abstract

Ipilimumab is a first-in-class immunological checkpoint blockade agent and monoclonal antibody against Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) that has demonstrated survival benefit and durable responses in patients with metastatic melanoma. To date, solid organ transplant recipients have been excluded from clinical trials with cancer immunotherapies on the basis of their concurrent treatment with immunosuppressive agents. We present the first case to our knowledge of a patient with advanced cutaneous melanoma receiving ipilimumab status post orthotopic liver transplantation with a partial response. Transaminitis was observed 4 months after administration of ipilimumab that resolved with close observation. No evidence of graft rejection has been observed to date. This case advocates for further investigation of the safety and efficacy of cancer immunotherapies in solid organ transplant recipients.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1186/s40425-015-0066-0

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Figure 1 Demonstration of changes in AST/ALT values over time with administration of ipilimumab; AST and ALT levels were measured weekly during the administration of ipilimumab. Sixteen weeks following initial induction, AST and ALT levels peaked at Grade 3. Resolution to Grade 1 was seen at Week 20, and monthly monitoring of liver function tests has been performed since, with continued evidence of stability. Arrows denote the times of administration of ipilimumab.CC BY · PubMed Central

Figure 2 Demonstration of radiographic response to ipilimumab; CT scans performed prior to and 12 weeks after initiation of therapy demonstrate regression of lung and liver metastases (arrows).CC BY · PubMed Central

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496
Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
Schadendorf, D., Hodi, F. S., Robert, C., Weber, J. S., Margolin, K., Hamid, O., Patt, D., Chen, T.-T., Berman, D. M., & Wolchok, J. D. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.2736 · Cited by 2,141
Prospective multicenter clinical trial of immunosuppressive drug withdrawal in stable adult liver transplant recipients
Benítez, C., Londoño, M., Miquel, R., Manzia, T. M., Abraldeṣ, J. G., Lozano, J. J., Martínez‐Llordella, M., López, M., Angelico, R., Bohne, F., et al. (2013) · Hepatology · doi:10.1002/hep.26426 · Cited by 322
Immunologic Basis of Graft Rejection and Tolerance Following Transplantation of Liver or Other Solid Organs
Fueyo, A. S., & Strom, T. B. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.10.059 · Cited by 237
Successful Administration of Ipilimumab to Two Kidney Transplantation Patients With Metastatic Melanoma
Lipson, E. J., Bodell, M. A., Kraus, E. S., & Sharfman, W. H. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.2314 · Cited by 158
Self-citation
Trial of complete weaning from immunosuppression for liver transplant recipients: Factors predictive of tolerance
de la Garza, R. G., Sarobe, P., Merino, J., Lasarte, J. J., D’Avola, D., Belsúe, V., Delgado, J. A., Silva, L., Iñarrairaegui, M., Sangro, B., et al. (2013) · Liver Transplantation · doi:10.1002/lt.23686 · Cited by 96
Malignant Melanoma in Solid Transplant Recipients
Brewer, J. D. (2011) · Archives of Dermatology · doi:10.1001/archdermatol.2011.159 · Cited by 93
Systematic review of melanoma incidence and prognosis in solid organ transplant recipients
Dahlke, E. J., Murray, C., Kitchen, J., & Chan, A. (2014) · Transplantation Research · doi:10.1186/2047-1440-3-10 · Cited by 80

Show all 12 references

Sorted by citations

Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
Postow, M. A., Sidlow, R., & Hellmann, M. D. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1703481 · Cited by 4,849
Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies
Naidoo, J., Page, D. B., Li, B. T., Connell, L. C., Schindler, K., Lacouture, M. E., Postow, M. A., & Wolchok, J. D. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv383 · Cited by 1,505
Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders
Johnson, D. B., Sullivan, R. J., Ott, P. A., Carlino, M. S., Khushalani, N. I., Ye, F., Guminski, A., Puzanov, I., Lawrence, D. P., Buchbinder, E. I., et al. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2015.4368 · Cited by 642
Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology
Thompson, J. A., Schneider, B. J., Brahmer, J., Andrews, S., Armand, P., Bhatia, S., Budde, L. E., Costa, L., Davies, M., Dunnington, D., et al. (2019) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2019.0013 · Cited by 570
Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference
Llovet, J. M., Villanueva, A., Marrero, J. A., Schwartz, M., Meyer, T., Galle, P. R., Lencioni, R., Greten, T. F., Kudo, M., Mandrekar, S. J., et al. (2021) · Hepatology · doi:10.1002/hep.31327 · Cited by 413
Immune checkpoint inhibitors in challenging populations
Johnson, D. B., Sullivan, R. J., & Menzies, A. M. (2017) · Cancer · doi:10.1002/cncr.30642 · Cited by 339
Immunotherapy of Hepatocellular Carcinoma: Facts and Hopes
Iñarrairaegui, M., Melero, I., & Sangro, B. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0289 · Cited by 235
Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: Review of the literature and personalized risk-based prevention strategy
Haanen, J., Ernstoff, M. S., Wang, Y., Menzies, A. M., Puzanov, I., Grivas, P., Larkin, J., Peters, S., Thompson, J. A., & Obeid, M. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.03.285 · Cited by 222
Liver transplantation immunology: immunosuppression, rejection, and immunomodulation
Montano-Loza, A. J., Rodríguez-Perálvarez, M. L., Pageaux, G.-P., Sanchez-Fueyo, A., & Feng, S. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.01.030 · Cited by 208
Pilot evaluation of PD-1 inhibition in metastatic cancer patients with a history of liver transplantation: the Mayo Clinic experience
DeLeon, T. T., Salomao, M. A., Aqel, B. A., Sonbol, M. B., Yokoda, R. T., Ali, A. H., Moss, A. A., Mathur, A. K., Chascsa, D. M., Rakela, J., et al. (2018) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2018.07.05 · Cited by 157
Immune checkpoint inhibitor therapy in solid organ transplant recipients: A patient-centered systematic review
Fisher, J., Zeitouni, N. C., Fan, W., & Samie, F. H. (2019) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2019.07.005 · Cited by 157
The Safety and Efficacy of Checkpoint Inhibitors in Transplant Recipients: A Case Series and Systematic Review of Literature
Kumar, V., Shinagare, A. B., Rennke, H. G., Ghai, S., Lorch, J. H., Ott, P. A., & Rahma, O. E. (2020) · The Oncologist · doi:10.1634/theoncologist.2019-0659 · Cited by 152
Immune Checkpoint Inhibitors in Organ Transplant Patients
Kittai, A. S., Oldham, H., Cetnar, J., & Taylor, M. (2017) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000180 · Cited by 151
Acute renal allograft rejection after immune checkpoint inhibitor therapy for metastatic melanoma
Spain, L. A., Higgins, R. M., Gopalakrishnan, K., Turajlic, S., Gore, M. E., & Larkin, J. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw130 · Cited by 145
Liver Allograft Failure After Nivolumab Treatment—A Case Report With Systematic Literature Research
Gassmann, D., Weiler, S., Mertens, J. C., Reiner, C. S., Vrugt, B., Nägeli, M., Mangana, J., Müllhaupt, B., Jenni, F., & Misselwitz, B. (2018) · Transplantation Direct · doi:10.1097/txd.0000000000000814 · Cited by 139
Fatal orthotopic liver transplant organ rejection induced by a checkpoint inhibitor in two patients with refractory, metastatic hepatocellular carcinoma
Friend, B. D., Venick, R. S., McDiarmid, S. V., Zhou, X., Naini, B. V., Wang, H., Farmer, D. G., Busuttil, R. W., & Federman, N. C. (2017) · Pediatric Blood & Cancer · doi:10.1002/pbc.26682 · Cited by 135
Impact of Immune-Modulatory Drugs on Regulatory T Cell
Furukawa, A., Wisel, S. A., & Tang, Q. (2016) · Transplantation · doi:10.1097/tp.0000000000001379 · Cited by 130
Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitors
Day, D., & Hansen, A. R. (2016) · BioDrugs · doi:10.1007/s40259-016-0204-3 · Cited by 117
Use of checkpoint inhibitors in liver transplant recipients
Munker, S., & Toni, E. N. D. (2018) · United European Gastroenterology Journal · doi:10.1177/2050640618774631 · Cited by 104
Checkpoint inhibitors in chronic kidney failure and an organ transplant recipient
Herz, S., Höfer, T., Papapanagiotou, M., Leyh, J., Meyenburg, S., Schadendorf, D., Ugurel, S., Roesch, A., Livingstone, E., Schilling, B., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.07.026 · Cited by 102
Renal complications of immune checkpoint blockade
Murakami, N., Motwani, S. S., & Riella, L. V. (2016) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2016.12.004 · Cited by 100
Chemotherapy and Transplantation: The Role of Immunosuppression in Malignancy and a Review of Antineoplastic Agents in Solid Organ Transplant Recipients
Krisl, J. C., & Doan, V. (2017) · American Journal of Transplantation · doi:10.1111/ajt.14238 · Cited by 103
Acute Severe Autoimmune Hepatitis: Corticosteroids or Liver Transplantation?
Rahim, M. N., Liberal, R., Miquel, R., Heaton, N. D., & Heneghan, M. A. (2019) · Liver Transplantation · doi:10.1002/lt.25451 · Cited by 91
Antitumor activity of nivolumab on hemodialysis after renal allograft rejection
Ong, M., Ibrahim, A. M., Bourassa‐Blanchette, S., Canil, C., Fairhead, T., & Knoll, G. A. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0171-8 · Cited by 81
Immune checkpoint blockade for organ transplant patients with advanced cancer: how far can we go?
De Bruyn, P., Van Gestel, D., Ost, P., Kruse, V., Brochez, L., Van Vlierberghe, H., Devresse, A., del Marmol, V., Le Moine, A., & Aspeslagh, S. (2019) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000505 · Cited by 79
Multidisciplinary approach for post-liver transplant recurrence of hepatocellular carcinoma: A proposed management algorithm
Au, K. P., & Chok, K. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i45.5081 · Cited by 79
Safety and efficacy of anti-PD-1 in patients with baseline cardiac, renal, or hepatic dysfunction
Kanz, B. A., Pollack, M. H., Johnpulle, R., Puzanov, I., Horn, L., Morgans, A., Sosman, J. A., Rapisuwon, S., Conry, R. M., Eroglu, Z., et al. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0166-5 · Cited by 75
Systematic Review of the Safety of Immune Checkpoint Inhibitors Among Kidney Transplant Patients
Manohar, S., Thongprayoon, C., Cheungpasitporn, W., Markovic, S. N., & Herrmann, S. M. (2019) · Kidney International Reports · doi:10.1016/j.ekir.2019.11.015 · Cited by 74
Monitoring and Management of Immune-Related Adverse Events Associated With Programmed Cell Death Protein-1 Axis Inhibitors in Lung Cancer
O'Kane, G. M., Labbé, C., Doherty, M. K., Young, K., Albaba, H., & Leighl, N. B. (2016) · The Oncologist · doi:10.1634/theoncologist.2016-0164 · Cited by 72
Immune Checkpoint Inhibitors and the Risk of Allograft Rejection: A Comprehensive Analysis on an Emerging Issue
Aguirre, L. E., Guzman, M. E., Lopes, G., & Hurley, J. (2019) · The Oncologist · doi:10.1634/theoncologist.2018-0195 · Cited by 68
A review of serious adverse effects under treatment with checkpoint inhibitors
Heinzerling, L., & Goldinger, S. M. (2017) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000358 · Cited by 67
Immune checkpoint inhibitor therapy in a liver transplant recipient with a rare subtype of melanoma: a case report and literature review
Kuo, J. C.-Y., Lilly, L., & Hogg, D. (2017) · Melanoma Research · doi:10.1097/cmr.0000000000000410 · Cited by 65
Immune checkpoint inhibitors in malignancies after liver transplantation: A systematic review and pooled analysis
Kayali, S., Pasta, A., Torres, M. C. P., Jaffe, A., Strazzabosco, M., Marenco, S., & Giannini, E. G. (2022) · Liver International · doi:10.1111/liv.15419 · Cited by 60
Immunotherapy and Liver Transplantation: A Narrative Review of Basic and Clinical Data
Wassmer, C., Hajji, S. E., Papazarkadas, X., Compagnon, P., Tabrizian, P., Lacotte, S., & Toso, C. (2023) · Cancers · doi:10.3390/cancers15184574 · Cited by 52
Cancer immunotherapy in a neglected population: The current use and future of T-cell-mediated checkpoint inhibitors in organ transplant patients
Chae, Y. K., Galvez, C., Anker, J. F., Iams, W. T., & Bhave, M. A. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.12.004 · Cited by 50
Utilization of Immunotherapy for the Treatment of Hepatocellular Carcinoma in the Peri-Transplant Setting: Transplant Oncology View
Abdelrahim, M., Esmail, A., Saharia, A., Abudayyeh, A., Abdel‐Wahab, N., Diab, A. K., Murakami, N., Kaseb, A. O., Chang, J. C., Gaber, A. O., et al. (2022) · Cancers · doi:10.3390/cancers14071760 · Cited by 47
Acute liver graft rejection after ipilimumab therapy
Dueland, S., Guren, T. K., Boberg, K. M., Reims, H. M., Grzyb, K., Aamdal, S., Julsrud, L., & Line, P. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx281 · Cited by 46
Ipilimumab for the treatment of advanced melanoma in six kidney transplant patients
Zehou, O., Leibler, C., Arnault, J., Sayegh, J., Montaudié, H., Rémy, P., Glotz, D., Cordonnier, C., Martin, L., & Lebbé, C. (2018) · American Journal of Transplantation · doi:10.1111/ajt.15071 · Cited by 45
Liver graft rejection following immune checkpoint inhibitors treatment: a review
Hu, B., Yang, X., & Sang, X. (2019) · Medical Oncology · doi:10.1007/s12032-019-1316-7 · Cited by 44
The Bad and the Good News on Cancer Immunotherapy: Implications for Organ Transplant Recipients
Maggiore, U., & Pascual, J. (2016) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2016.08.002 · Cited by 43
Immune checkpoint inhibitors for solid organ transplant recipients: clinical updates
Kawashima, S., Joachim, K., Abdelrahim, M., Abudayyeh, A., Jhaveri, K. D., & Murakami, N. (2022) · Korean Journal of Transplantation · doi:10.4285/kjt.22.0013 · Cited by 39
Cutaneous squamous cell carcinoma in the organ transplant recipient
Bibee, K., Swartz, A., Sridharan, S., Kürten, C. H. L., Wessel, C. B., Skinner, H. D., & Zandberg, D. P. (2020) · Oral Oncology · doi:10.1016/j.oraloncology.2019.104562 · Cited by 40
Immunotherapy after liver transplantation: Where are we now?
Au, K. P., & Chok, K. (2021) · World Journal of Gastrointestinal Surgery · doi:10.4240/wjgs.v13.i10.1267 · Cited by 39
Immune Checkpoint Inhibition in Non-Melanoma Skin Cancer: A Review of Current Evidence
Stonesifer, C. J., Djavid, A. R., Grimes, J. M., Khaleel, A. E., Soliman, Y. S., Maisel-Campbell, A. L., Garcia-Saleem, T. J., Geskin, L. J., & Carvajal, R. D. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.734354 · Cited by 36
Self-citation
Ipilimumab in melanoma
Specenier, P. M. (2016) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2016.1211936 · Cited by 38
Safe Administration of An Anti-PD-1 Antibody to Kidney-transplant Patients: 2 Clinical Cases and Review of the Literature
Winkler, J. K., Gutzmer, R., Bender, C., Lang, N., Zeier, M. G., Enk, A., & Hassel, J. C. (2017) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000188 · Cited by 35
Biomarkers in hepatocellular carcinoma: an overview
Juárez-Hernández, E., Motola‐Kuba, D., Chávez-Tapia, N. C., Uribe, M., & Barbero-Becerra, V. J. (2017) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2017.1311785 · Cited by 34
Immune Checkpoint Inhibitors in Transplantation—A Case Series and Comprehensive Review of Current Knowledge
Delyon, J., Zuber, J., Dorent, R., Poujol‐Robert, A., Péraldi, M., Anglicheau, D., & Lebbé, C. (2020) · Transplantation · doi:10.1097/tp.0000000000003292 · Cited by 34
Immune checkpoint blockade for organ-transplant recipients with cancer: A review
Rünger, A., Schadendorf, D., Hauschild, A., & Gebhardt, C. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.08.010 · Cited by 36
Ipilumumab for Hepatocellular Cancer in a Liver Transplant Recipient, with Durable Response, Tolerance and Without Allograft Rejection
Pandey, A., & Cohen, D. J. (2020) · Immunotherapy · doi:10.2217/imt-2020-0014 · Cited by 33
Safe and effective administration of T-VEC in a patient with heart transplantation and recurrent locally advanced melanoma
Schvartsman, G., Perez, K., Flynn, J. E., Myers, J. N., & Tawbi, H. A. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0250-5 · Cited by 31
Allograft rejection following immune checkpoint inhibitors in solid organ transplant recipients: A safety analysis from a literature review and a pharmacovigilance system
Cui, X., Yan, C., Xu, Y., Li, D., Guo, M., Sun, L., & Zhu, Z. (2022) · Cancer Medicine · doi:10.1002/cam4.5394 · Cited by 29
The role of calcium hydroxylapatite (Radiesse) in nonsurgical aesthetic rejuvenation.
Lizzul, P. F., & Narurkar, V. A. (2010) · PubMed · Cited by 30
New Systemic Treatments in Advanced Hepatocellular Carcinoma
Sanduzzi‐Zamparelli, M., Díaz‐González, Á., & Reig, M. (2018) · Liver Transplantation · doi:10.1002/lt.25354 · Cited by 29
Immunotherapy for hepatocellular carcinoma recurrence after liver transplantation, can we harness the power of immune checkpoint inhibitors?
Jiang, J., Huang, H., Chen, R., Lin, Y., & Ling, Q. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1092401 · Cited by 28
Immune Checkpoint Inhibitors in the Cancer Patient with An Organ Transplant
Wanchoo, R., Riella, L. V., Uppal, N. N., Lopez, C. A., Nair, V. V., Devoe, C., & Jhaveri, K. D. (2017) · Journal of Onco-Nephrology · doi:10.5301/jo-n.5000006 · Cited by 26
Checkpoint inhibitor use in two heart transplant patients with metastatic melanoma and review of high-risk populations
Grant, M. J., DeVito, N., & Salama, A. K. S. (2018) · Melanoma Management · doi:10.2217/mmt-2018-0004 · Cited by 24
Cancer in Solid Organ Transplant Recipients: There Is Still Much to Learn and Do
Engels, E. A. (2017) · American Journal of Transplantation · doi:10.1111/ajt.14140 · Cited by 26
Immune Checkpoint Inhibitors in Patients with Recurrent Hepatocellular Carcinoma after Liver Transplantation: A Case Report and Literature Review
Qiu, J., Tang, W., & Du, C. (2020) · Current Cancer Drug Targets · doi:10.2174/1568009620666200520084415 · Cited by 24
Graft rejection after immune checkpoint inhibitor therapy in solid organ transplant recipients
Smedman, T. M., Line, P., Guren, T. K., & Dueland, S. (2018) · Acta Oncologica · doi:10.1080/0284186x.2018.1479069 · Cited by 24
Immunotherapy in liver transplantation for hepatocellular carcinoma: Pros and cons
Luo, Y., Teng, F., Fu, H. Y., & Ding, G. (2022) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v14.i1.163 · Cited by 23
Holistic Management of Hepatocellular Carcinoma: The Hepatologist’s Comprehensive Playbook
Jaffe, A., Taddei, T. H., Giannini, E., Ilagan-Ying, Y. C., Colombo, M., & Strazzabosco, M. (2022) · Liver international (Print) · doi:10.1111/liv.15432 · Cited by 23
Immune checkpoint inhibitor therapy for malignant tumors in liver transplantation recipients: A systematic review of the literature
Zhang, P., Zhu, G., Li, L., Lai, G., Wang, Z., Sun, C., Xia, W., & Wu, L. (2022) · Transplantation Reviews · doi:10.1016/j.trre.2022.100712 · Cited by 22
Tolerability of immune checkpoint inhibition cancer therapy in a cardiac transplant patient
Gastman, B., & Ernstoff, M. S. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw293 · Cited by 21
Immune Checkpoint Inhibitors for Solid Tumors in the Adjuvant Setting: Current Progress, Future Directions, and Role in Transplant Oncology
Abboud, K., Umoru, G., Esmail, A., Abudayyeh, A., Murakami, N., Al-Shamsi, H. O., Javle, M. M., Saharia, A., Connor, A. A., Kodali, S., et al. (2023) · Cancers · doi:10.3390/cancers15051433 · Cited by 21
PD-1 Blockade in a Liver Transplant Recipient With Microsatellite Unstable Metastatic Colorectal Cancer and Hepatic Impairment
Chen, J. A., Esteghamat, N., Kim, E. J.-H., García, G., Gong, J., Fakih, M., Bold, R. J., & Cho, M. T. (2019) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2019.7328 · Cited by 18
Immune checkpoint inhibitors in liver transplant recipients - a review of current literature
Yin, C., Baba, T., He, A. R., & Smith, C. I. (2021) · Hepatoma Research · doi:10.20517/2394-5079.2021.11 · Cited by 17
The safety of pembrolizumab in metastatic melanoma and rheumatoid arthritis
Puri, A., & Homsi, J. (2017) · Melanoma Research · doi:10.1097/cmr.0000000000000387 · Cited by 17
When immunotherapy meets liver transplantation for hepatocellular carcinoma: A bumpy but promising road
Gu, Y., Xu, S., Wang, Z., Yang, J., Zheng, S., Wei, Q., Liu, Z., & Xu, X. (2023) · Chinese Journal of Cancer Research · doi:10.21147/j.issn.1000-9604.2023.02.02 · Cited by 17
Immune-checkpoint inhibitors to treat cancers in specific immunocompromised populations: a critical review
Babey, H., Quéré, G., Descourt, R., Calloch, R. L., Lanfranco, L., Nousbaum, J., Cornec, D., Tison, A., & CHOUAID, C. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1499468 · Cited by 18
Utilization of Immunotherapy as a Neoadjuvant Therapy for Liver Transplant Recipients with Hepatocellular Carcinoma
Abdelrahim, M., Esmail, A., Divatia, M. K., Xu, J., Kodali, S., Victor, D. W., Brombosz, E. W., Connor, A. A., Saharia, A., Elaileh, A., et al. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13113068 · Cited by 15
Immunotherapy in organ-transplanted cancer patients: efficacy and risk of organ rejection
Ros, J., Matos, I. G., & Martín-Liberal, J. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz129 · Cited by 15
Immunotherapy and Liver Transplantation
Tabrizian, P., Yu, A. T., Debnath, N., Myers, B., & Marron, T. U. (2023) · Surgical Clinics of North America · doi:10.1016/j.suc.2023.07.009 · Cited by 13
Liver Transplantation for Hepatocellular Carcinoma in the Era of Immune Checkpoint Inhibitors
Stefano, N. D., Patrono, D., Colli, F., Rizza, G., Paraluppi, G., & Romagnoli, R. (2024) · Cancers · doi:10.3390/cancers16132374 · Cited by 13
Immune checkpoint inhibitors in the management of malignancies in transplant recipients
Regalla, D. K. R., Williams, G. R., & Paluri, R. K. (2018) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2018-136081 · Cited by 13
Primary prophylaxis with mTOR inhibitor enhances T cell effector function and prevents heart transplant rejection during talimogene laherparepvec therapy of squamous cell carcinoma
Joo, V., Abdelhamid, K., Noto, A., Latifyan, S., Martina, F., Daoudlarian, D., Micheli, R. D., Pruijm, M. T., Peters, S., Hullin, R., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-47965-3 · Cited by 13
Immuno-oncology for Hepatocellular Carcinoma
Armstrong, S. A., & He, A. R. (2020) · Clinics in Liver Disease · doi:10.1016/j.cld.2020.07.007 · Cited by 10
An analysis report on the application of immune checkpoint inhibitors after liver transplantation
Xie, M., Dang, Z.-P., Sun, X., Zhang, B., Zhang, Q., Tian, Q., Cai, J.-Z., & Rao, W. (2022) · Therapeutic Advances in Chronic Disease · doi:10.1177/20406223221099334 · Cited by 9
A systematic review of yttrium-90 radioembolization for unresectable liver metastases of melanoma
Jia, Z., Jiang, G., Zhu, C., Wang, K., Li, S., & Qin, X. (2017) · European Journal of Radiology · doi:10.1016/j.ejrad.2017.05.005 · Cited by 9
Application of Immune Checkpoint Inhibitors in Solid Organ Transplantation Recipients: A Systematic Review
Miao, K., & Zhang, L. (2021) · Interdisciplinary Sciences Computational Life Sciences · doi:10.1007/s12539-021-00437-4 · Cited by 9
Weighing Up the Pros and Cons of Immune Checkpoint Inhibitors in The Treatment of Melanoma
Spain, L. A., & Larkin, J. (2016) · Immunotherapy · doi:10.2217/imt.16.6 · Cited by 9
Suppressing, stimulating and/or inhibiting: The evolving management of HCC patient after liver transplantation
Marco, L. D., Romanzi, A., Pivetti, A., Maria, N. D., Ravaioli, F., Salati, M., Villa, E., Benedetto, F. D., Magistri, P., Dominici, M., et al. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104607 · Cited by 8
Management of checkpoint inhibitor-associated renal toxicities
Vanoverbeke, L., & Sprangers, B. (2017) · Expert Review of Quality of Life in Cancer Care · doi:10.1080/23809000.2017.1369045 · Cited by 7
Role of Intrahepatic Regional Immunity in Post-Transplant Cancer Recurrence
Liu, J., Lo, C. M., & Man, K. (2021) · Engineering · doi:10.1016/j.eng.2021.11.012 · Cited by 7
Melanoma en pacientes receptores de un trasplante de órgano sólido
González‐Cruz, C., Ferrándiz‐Pulido, C., & García-Patos, V. (2020) · Actas Dermo-Sifiliográficas · doi:10.1016/j.ad.2020.11.005 · Cited by 8
Cutaneous squamous cell carcinoma in solid organ transplant recipients: Current therapeutic and screening strategies
Struckmeier, A., Gosau, M., & Smeets, R. (2024) · Transplantation Reviews · doi:10.1016/j.trre.2024.100882 · Cited by 7
Immune checkpoint inhibitors in liver transplantation: Current practice, challenges, and opportunities
Martin, S. P., Mehta, N. J., & Emamaullee, J. A. (2024) · Liver Transplantation · doi:10.1097/lvt.0000000000000350 · Cited by 6
Use of immune checkpoint inhibitors in solid organ transplant recipients with advanced cutaneous malignancies
Ji, S., Liu, H., Pachella, L. A., Stephenson, R. D., Groisberg, R., & Weiss, S. A. (2023) · Frontiers in Transplantation · doi:10.3389/frtra.2023.1284740 · Cited by 5
Der Einsatz der immunonkologischen Therapie beim hepatozellulären Karzinom im Kontext der Lebertransplantation Eine interdisziplinäre Risiko-Nutzen-Abwägung
Vogel, A., Sterneck, M. R., Vondran, F. W. R., Waidmann, O., Klein, I., Lindig, U., Nadalin, S., Settmacher, U., Tacke, F., Schlitt, H. J., et al. (2021) · Zeitschrift für Gastroenterologie · doi:10.1055/a-1649-8643 · Cited by 5
Melanoma in Solid Organ Transplant Recipients
González‐Cruz, C., Ferrándiz‐Pulido, C., & García-Patos, V. (2021) · Actas Dermo-Sifiliográficas · doi:10.1016/j.adengl.2021.01.011 · Cited by 5
Skin Cancers and Lung Transplant
Wilken, R., Carucci, J. A., & Stevenson, M. L. (2021) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0041-1728798 · Cited by 5
Camrelizumab (SHR-1210) treatment for recurrent hepatocellular carcinoma after liver transplant: A report of two cases
Dai, T., Yang, Q., Zhang, Y., Ye, L., Li, H., Yi, S., Liu, W., Yang, Y., & Wang, G. (2021) · Liver Research · doi:10.1016/j.livres.2021.06.002 · Cited by 5
Cancer immunotherapy in patients with new or recurrent malignancies after liver transplantation
Liu, M., Guo, W., & Zhang, S. (2017) · International Journal of Surgery Oncology · doi:10.1097/ij9.0000000000000049 · Cited by 5
Immune Checkpoint Inhibitors and Liver Transplantation: Case Report and Review of the Literature
Skočilić, I., Košić, A., Badovinac, I., Kanižaj, T. F., Dobrila-Dintinjana, R., Kolak, M., Bukovica, A. M., Ropac, S., & Mikolašević, I. (2025) · Clinical Case Reports · doi:10.1002/ccr3.70412 · Cited by 2
Immune checkpoints inhibitors for solid tumours after allogeneic haematopoietic stem-cell transplantation: About four clinical cases
Monneur, A., Monnier, J., Gaudy‐Marqueste, C., Devillier, R., & Sabatier, R. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.05.023 · Cited by 2
Anti-PD-1 Monotherapy Versus Anti-PD1 Plus Anti-CTLA4 in Advanced Melanoma: How do we Decide?
Au, L., O’Reilly, A., & Larkin, J. (2017) · Melanoma Management · doi:10.2217/mmt-2017-0016 · Cited by 2
Cutaneous Head and Neck Cancers in the High-Risk Immunosuppressed Population
Choi, K. Y., & Schmalbach, C. E. (2021) · Otolaryngologic Clinics of North America · doi:10.1016/j.otc.2020.11.012 · Cited by 2
Immune Checkpoint Inhibitors - New Insights and Recent Progress
Raza, A. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.100958 · Cited by 2
Toxicities in Immune Checkpoint Inhibitors
Lee, S. S., Loecher, M., & Puzanov, I. J. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-54948-6.00011-1 · Cited by 2
Immunotherapy use in kidney transplant recipients: Immune checkpoint inhibitors and CAR-T cell therapy
Bassil, C., & Khimani, F. (2020) · Journal of Onco-Nephrology · doi:10.1177/2399369320953163 · Cited by 2

Authors: Morales, R. E., Shoushtari, A. N., Walsh, M. M., Grewal, P., Lipson, E. J., & Carvajal, R. D.
Affiliations: Columbia University (US)
Memorial Sloan Kettering Cancer Center (US)
Columbia University Irving Medical Center (US)
Icahn School of Medicine at Mount Sinai (US)
Johns Hopkins University (US)
Corresponding author: Carvajal, Richard D
ORCID: Shoushtari, Alexander N
Lipson, Evan J
Carvajal, Richard D
Venue: Journal for ImmunoTherapy of Cancer
Publisher: BMJ
Published: 2015-06-16
Volume: 3
Issue: 1
Pages: 22-22
ISSN: 2051-1426 (ISSN-L)
DOI: 10.1186/s40425-015-0066-0
PMC: PMC4469313
OpenAlex: W1517732299
Cited by: 110
References: 12
Citations by year: 2026: 1 · 2025: 1 · 2024: 6 · 2023: 9 · 2022: 11 · 2021: 12 · 2020: 10 · 2019: 9 · 2018: 13 · 2017: 21 · 2016: 13 · 2015: 2
FWCI: 7.13
Type: journal article
Language: en
Open access: gold
doi.org
Licence: creativecommons.org/licenses/by/4.0 (tdm)
Locations: Journal for ImmunoTherapy of Cancer (publishedVersion)
Europe PMC (PubMed Central) (publishedVersion, cc-by)
PubMed Central (publishedVersion, cc-by)
PubMed (publishedVersion)
Columbia Academic Commons (Columbia University)
Funders: National Cancer Institute (P30CA008748)
Topics: Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords: ipilimumab, liver transplantation, CTLA-4 blockade, cancer immunotherapy, solid organ transplant recipients, elevated liver enzymes, graft rejection, immunosuppression, treatment efficacy and safety

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Safety and efficacy of ipilimumab to treat advanced melanoma in the setting of liver transplantation

Abstract

Overview

Integrity signals

Figures

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks